Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by CPET in Subjects With WHO Group 1 Pulmonary Hypertension Who Recently Initiated Therapy

NCT04084678 is registered in ClinicalTrials.gov with United Therapeutics as lead sponsor.

NCT NCT04084678
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04084678 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by CPET in Subjects With WHO Group 1 Pulmonary Hypertension Who Recently Initiated Therapy
Lead sponsor
United Therapeutics
Phase
Phase 3
Overall status
Terminated
Start date
January 20, 2021
Completion date
April 12, 2023
Enrollment
10 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary arterial hypertension, pulmonary hypertension